Considering treatment with Venclexta (or its myriad names) or Ibrurinib (and its myriad names) or ACP196/acalabrutinib (and I'm sure it will soon gain another name)? Then make certain that you first read this guest blog:
cll-nhl.com/2016/04/venclex...
Incidentally, I'd suggest that the word 'except' was not intended in the first sentence of the section: 'Should I run off to the nearest major cancer center to be treated with this new agent?
If you do not have the 17-p deletion mutation, then at this time you could only receive this drug, except as part of a clinical trial.'
Neil